Informations générales (source: ClinicalTrials.gov)
Interventional
N/A
Centre Hospitalier Universitaire de Nice (Voir sur ClinicalTrials)
juillet 2013
29 juin 2024
ALS is a severe progressive neurodegenerative disease characterized by degeneration motor
neurons leading to death in 3 to 5 years. Gradually in time, the patient deprived of all
motor skills as well as the possibility of communication written and oral developing a
state close Locked In Syndrome (LIS). The main objective is to establish the feasibility
of brain-computer interface using the pathological condition, with dependent disabled
subjects as a means of communication.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hôpital de l'Archet I - 06202 - Nice - France | Claude DESNUELLE, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- age >= 18
- have a diagnosis of ALS suspected, possible, probable with EMG
- be able to follow the study process and to comply with the schedule of visits upon
entry into the study
- understand the purpose of the study
- expressing P300 wave in the conditions of the study
- age >= 18
- have a diagnosis of ALS suspected, possible, probable with EMG
- be able to follow the study process and to comply with the schedule of visits upon
entry into the study
- understand the purpose of the study
- expressing P300 wave in the conditions of the study
- have a mental illness or clinical dementia defined clinically significant may hinder
the patient's ability to follow the procedures of the study
- have a significant history of photosensitive epilepsy
- have a history of allergy to the gel used for the electrodes
- Major protected by law (guardianship, curators)
- have uncorrectable visual disorders
- not being able to maintain a sitting position and focus on a computer screen for
more than 30 min.